Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
PE
PHARMACEUTICAL ECONSULTING A/S
aktivCVR 30815378AktieselskabNaverland 2, 10, 2600 GlostrupAndre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.
- Latest accounts
- 2025
- Statement scope
- Standalone
- Verified
- 05 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2025
Revenue
Data quality concern—
Data quality concern
Operating profit
DKK -1.3m
Latest period
Source details
Source: dk-regnskabsdata-live-30815378-1793912085249
Document: dk-regnskabsdata-30815378-AZ2b57IPJ8g52wzXZuBN-1
XBRL: fsa:ProfitLossFromOrdinaryOperatingActivities
Period: 01 Oct 2024 - 30 Sept 2025
Technical details
Context: ID_0
Unit: DKK
Net result
DKK -1.1m
Latest period
Source details
Source: dk-regnskabsdata-live-30815378-1793912085249
Document: dk-regnskabsdata-30815378-AZ2b57IPJ8g52wzXZuBN-1
XBRL: fsa:ProfitLoss
Period: 01 Oct 2024 - 30 Sept 2025
Technical details
Context: ID_0
Unit: DKK
Equity
DKK 5.2m
Equity ratio: 48.6%
Source details
Source: dk-regnskabsdata-live-30815378-1793912085249
Document: dk-regnskabsdata-30815378-AZ2b57IPJ8g52wzXZuBN-1
XBRL: fsa:Equity
Period: 01 Oct 2024 - 30 Sept 2025
Technical details
Context: ID_9
Unit: DKK
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2022 | — | DKK 779.6k |
| 2023 | — | DKK -383.6k |
| 2024 | — | DKK -643.9k |
| 2025 | — | DKK -1.1m |